Fig. 1: Targeting complement in SARS-CoV-2-associated lung injury. | Nature Reviews Immunology

Fig. 1: Targeting complement in SARS-CoV-2-associated lung injury.

From: Complement as a target in COVID-19?

Fig. 1

Complement activation may contribute to the maladaptive inflammatory response seen in some patients with severe COVID-19. Inhibition of C3 or C5 may have therapeutic potential. ARDS, acute respiratory distress syndrome.

Back to article page